Agilent's stock is in a recovery uptrend, with a 1-year price change of +15.14%, though it remains 13.5% below its 52-week high of $160.27. The current price of $138.57 sits at 86.5% of the 52-week range (from low $108.35 to high $160.27), indicating the stock is in the upper half of its range but not yet at overbought levels. This positioning suggests a constructive trend with room for further upside if momentum persists, though the proximity to the high warrants caution for potential resistance. Short-term momentum is accelerating, with a 1-month change of +5.27% and a 3-month change of +19.92%, both outpacing the S&P 500's respective gains of 0.78% and 3.5%. This divergence from the 1-year trend (which lagged the S&P's 16.47% gain) signals a potential shift in relative strength, as the stock has outperformed the market by 4.49% over the past month and 16.42% over three months. The recent surge following a strong earnings beat on May 28, 2026, confirms a bullish catalyst-driven move, though the RSI is not provided to assess overbought conditions. Key support lies at the 52-week low of $108.35, while resistance is at the 52-week high of $160.27. A breakout above $160.27 would signal a resumption of the long-term uptrend and could target new highs, while a breakdown below $108.35 would indicate a bearish reversal. With a beta of 1.255, Agilent is 25.5% more volatile than the market, meaning it amplifies market moves—a factor that increases risk but also offers higher potential returns in bullish phases.

Agilent's revenue trajectory is accelerating, with the most recent quarter (Q2 FY2026, ended April 30, 2026) reporting revenue of $1.835 billion, a 10.01% year-over-year increase from $1.668 billion in the prior-year quarter. This marks a significant acceleration from the 3.4% growth seen in Q1 FY2026 and the 7.1% growth in Q4 FY2025, driven by strength in the Life Sciences and Applied Markets segment ($732 million) and Agilent CrossLab ($759 million). The Applied Markets segment contributed $344 million, but its growth rate is not separately disclosed. The multi-quarter trend shows a clear inflection point, with revenue growth re-accelerating from a trough of 0.5% in Q3 FY2025 to double digits, supporting the investment case for a cyclical recovery in end markets. Profitability is robust and improving, with net income of $339 million in Q2 FY2026, up 57.7% from $215 million in the same quarter last year. Gross margin expanded to 54.99% from 51.92% a year ago, reflecting better cost management and mix shift toward higher-margin consumables and services. Operating margin improved to 21.74% from 17.99%, and net margin rose to 18.47% from 12.89%. The company is consistently profitable, with a trailing twelve-month net income of $1.414 billion (sum of last four quarters), and margins are above industry averages for diagnostics and research firms, indicating strong pricing power and operational efficiency. Agilent maintains a healthy balance sheet with a debt-to-equity ratio of 0.50 and a current ratio of 1.96, indicating ample liquidity. Free cash flow (FCF) for the trailing twelve months is $1.256 billion, providing a FCF yield of approximately 3.0% based on the current market cap of $41.42 billion. The company generated $277 million in operating cash flow in Q2 FY2026, covering capital expenditures of $93 million and dividends of $72 million, with $65 million in share repurchases. Return on equity (ROE) stands at 19.33%, reflecting efficient capital allocation, while the interest coverage ratio of 15.96x indicates low financial risk. The company's ability to self-fund growth and return capital to shareholders underscores its financial strength.